Weekly Top News – IBD – September 28, 2020

September 28, 2020

etrasimod (APD334) / Arena
Etrasimod: Completion of enrollment of P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in Q4 2020 (Arena) – Sep 24, 2020 – Jefferies Virtual Next Generation IBD Therapeutics Summit: Top-line data from P3 ELEVATE UC 52 trial for ulcerative colitis in Q4 2021; Top-line data from P3 ELEVATE UC 12 trial (NCT03996369) for ulcerative colitis in Q4 2021 
[Screenshot]

 

Jyseleca (filgotinib) / Gilead
Stock market look: Galapagos on track in Japan and EU [Google Translation] (DeAandeelhouder.nl) – Sep 24, 2020 – “The filing for ulcerative colitis in the United States will depend on the results the Manta study produces in the first half of 2021…The Phase 3 Diversity study of filgotinib with Crohn’s disease is expected to provide data in 2022.”

 

etrasimod (APD334) / Arena
Etrasimod: Initiation of trial for ulcerative colitis in early 2021 (Arena) – Sep 24, 2020 – Jefferies Virtual Next Generation IBD Therapeutics Summit 
[Screenshot]

 

Entyvio (vedolizumab) / Takeda
CHRONOS: A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD) (clinicaltrials.gov) – Sep 25, 2020 – P=N/A; N=60; Completed; Sponsor: Takeda; Active, not recruiting –> Completed; N=150 –> 60

 

ABX464 / Abivax
Abivax Presents First-Half 2020 Financial Results and Operations Update (Yahoo Finance) – Sep 26, 2020 – “77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the end of 2020. ABX464 pivotal Phase 2b/3 trial for Crohn’s disease planned with anticipated start of patient recruitment in Q1 2021….”

No Comments

Post a Comment

Comment
Name
Email
Website